Table 2 Cost comparison of economic burden of HSV by WHO region and country income group (2016)
GUD due to HSV-1 (I$ million, %) | GUD due to HSV-2 (I$ million, %) | Neonatal herpes due to HSV-1 (I$ million, %) | Neonatal herpes due to HSV-2 (I$ million, %) | HIV-attributable to HSV-2 (I$ million, %) | |
|---|---|---|---|---|---|
By WHO region | |||||
Global | 3988 (100%) | 30,807 (100%) | 61 (100%) | 53 (100%) | 352 (100%) |
African | - | 3354 (10·9%) | 0.0 (0·0%) | 6 (12·1%) | 219 (62·3%) |
Americas | 1956 (49·0%) | 6486 (21·1%) | 36 (58·9%) | 22 (41·1%) | 78 (22·2%) |
Eastern Mediterranean | 194 (4·9%) | 1749 (5·7%) | 1·5 (2·4%) | 3 (6·5%) | 0·8 (0·2%) |
Europe | 902 (22·6%) | 4040 (13·1%) | 13 (20·6%) | 10 (18·9%) | 41 (11·5%) |
South-East Asia | 16 (0·4%) | 3879 (12·6%) | 0·1 (0·2%) | 1·1 (2·0%) | 6 (1·6%) |
Western Pacific | 920 (23·1%) | 11,299 (36·7%) | 11 (17·4%) | 10 (19·4%) | 8 (2·2%) |
By World Bank income level | |||||
Global | 3988 (100%) | 30,807 (100%) | 61 (100%) | 53 (100%) | 352 (100%) |
High | 2219 (55·6%) | 9589 (31·1%) | 41 (66·9%) | 30 (56·7%) | 92 (26·1%) |
Upper-middle | 1501 (37·6%) | 13,586 (44·1%) | 18 (29·7%) | 15 (28·7%) | 199 (56·5%) |
Lower-middle | 238 (6·0%) | 6612 (21·5%) | 2 (3·3%) | 6 (11·3%) | 47 (13·4%) |
Low | 30 (0·8%) | 1020 (3·3%) | 0·1 (0·2%) | 2 (3·3%) | 14 (4·0%) |